Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience

International Journal of Colorectal Disease

Volumn 26, Issue 11, 2011, Pages 1435-1444

  Rizzo, Gianluca ^a   Armuzzi, Alessandro ^b   Pugliese, Daniela ^b   Verbo, Alessandro ^a   Papa, Alfredo ^b   Mattana, Claudio ^a   Rapaccini, Gian Lodovico ^b   Guidi, Luisa ^b   Coco, Claudio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anti TNF alpha drugs; Corticosteroids; Crohn's disease; Postoperative complications; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ANTIBIOTIC AGENT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL SURGERY; ADOLESCENT; ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL MOTILITY DISORDER; HEPATORENAL SYNDROME; HUMAN; INFECTION RATE; ITALY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURGICAL MORTALITY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; ITALY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 80755153710     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-011-1236-2     Document Type: Article

References (42)

1. A Dignass G Van Assche JO Lindsay, et al. 2010 The second European evidenced-based consensus on the diagnosis and management of Crohn's disease: current management J Crohns Colitis 4 28 62 21122489 10.1016/j.crohns.2009.12. 002 1:STN:280:DC%2BC3M%2Fjs1OmsA%3D%3D
2. L Peyrin-Biroulet P Deltenre N de Suray, et al. 2008 Efficacy and safety of anti-tumor necrosis factor agents in Crohn's disease: a meta-analysis of placebo-controlled trials Clin Gastroenterol Hepatol 6 644 653 18550004 10.1016/j.cgh.2008.03.014 1:CAS:528:DC%2BD1cXos1WjsLg%3D (Pubitemid 351783447)
3. A Orlando A Armuzzi C Papi The Italian Society of Gastroenterology (SIGE) and The Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD), et al. 2011 Clinical Practice Guideline: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease Dig Liver Dis 43 1 20 20843756 10.1016/j.dld.2010.07.010
4. G D'Haens F Baert G Van Assche Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club, et al. 2008 Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Lancet 371 660 667 18295023 10.1016/S0140-6736(08)60304-9 (Pubitemid 351284485)
5. JF Colombel WJ Sandborn W Reinisch, et al. 2010 Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 1383 1395 20393175 10.1056/NEJMoa0904492 1:CAS:528:DC%2BC3cXkslajt78%3D
6. A Armuzzi B De Pascalis P Fedeli F De Vincentis A Gasbarrini 2008 Infliximab in Crohn's disease: early and long-term treatment Dig Liver Dis 40 Suppl 2 S271 S279 18599000 10.1016/S1590-8658(08)60537-X 1:CAS:528: DC%2BD1cXptVGru7Y%3D (Pubitemid 351878071)
7. SPL Travis EF Stange L Lemann, et al. 2008 European evidenced-based consensus on the management of ulcerative colitis: current management J Crohn's Colitis 2 24 62 10.1016/j.crohns.2007.11.002 (Pubitemid 351179488)
8. P Rutgeerts WJ Sandborn B Feagan, et al. 2005 Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 233 2462 2473 10.1056/NEJMoa050516 (Pubitemid 41770166)
9. G D'Haens WJ Sandborn BG Feagan, et al. 2007 Clinical trials of medical therapy in adults with ulcerative colitis Gastroenterology 132 763 786 17258735 10.1053/j.gastro.2006.12.038
10. G Järnerot E Hertervig I Friis-Liby, et al. 2005 Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study Gastroenterology 128 1805 1811 15940615 10.1053/j.gastro.2005.03.003 (Pubitemid 40824691)
11. A Kohn M Daperno A Armuzzi, et al. 2007 Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up Aliment Pharmacol Ther 26 747 756 17697208 10.1111/j.1365-2036.2007. 03415.x 1:CAS:528:DC%2BD2sXhtV2mtbbE (Pubitemid 47246204)
12. JF Colombel EV Loftus Jr WJ Tremaine, et al. 2004 Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy Am J Gastroenterol 99 878 883 15128354 10.1111/j.1572-0241.2004.04148.x 1:CAS:528: DC%2BD2cXlt1Cjur4%3D (Pubitemid 39090217)
13. L Marchal G D'Haens G Van Assche, et al. 2004 The risk of postoperative complications associated with Infliximab therapy for Crohn's disease: a controlled cohort study Aliment Pharmacol Ther 19 749 754 15043515 10.1111/j.1365-2036.2004.01904.x 1:CAS:528:DC%2BD2cXktVGnu7Y%3D (Pubitemid 38496640)
14. A Brzezinski l Armstrong GA De Real, et al. 2002 Infliximab does not increase the risk of complications in the perioperative period in patients with Crohn's disease Gastroenterology 122 A617
15. Kasparek MS, Bruckmeier A, Beigel F, et al (2010) Effect of infliximab on postoperative complications in patients with Crohn 's disease undergoing abdominal surgery. Abstract DDW
16. CR Selvasekar RR Cima DW Larson, et al. 2007 Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis J Am Coll Surg 204 956 962 17481518 10.1016/j.jamcollsurg.2006.12.044 (Pubitemid 46661200)
17. IJ Mor JD Vogel A da Luz Moreira, et al. 2008 Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy Dis Colon Rectum 51 8 1202 1207 18536964 10.1007/s10350-008-9364-7 1:STN:280:DC%2BD1cvnslCitA%3D%3D
18. SJ Schluender A Ippoliti M Dubinsky, et al. 2007 Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 50 11 1747 1753 10.1007/s10350-007-9008-3 17704969 10.1007/s10350-007-9008-3 (Pubitemid 350077092)
19. M Ferrante A D'Hoore S Vermeire, et al. 2009 Corticosteroids but not Infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis Inflamm Bowel Dis 15 7 1062 1070 19161179 10.1002/ibd.20863 1:STN:280:DC%2BD1MvhvFejtw%3D%3D
20. H Kunitake R Hodin PC Shellito, et al. 2008 Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications J Gastrointest Surg 12 1730 1736 18709514 10.1007/s11605-008-0630-8
21. L Bordeianou H Kunitake P Shellito, et al. 2010 Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery Int J Colorectal Dis 25 3 401 404 19798508 10.1007/s00384-009-0800-5
22. Coquet-Reinier B, Berdah SV, Grimaud JC, et al (2010) Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a case-matched study. Surg Endosc
23. F Cornillie D Shealy G D'Haens, et al. 2001 Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease Aliment Pharmacol Ther 15 463 473 11284774 10.1046/j.1365-2036.2001.00956.x 1:CAS:528:DC%2BD3MXjtVyis7w%3D (Pubitemid 32242771)
24. Nestorov I (2005) Clinical pharmacokinetics of TNF antagonist: how do they differ? Sem Art Rheum
25. PC Taylor 2010 Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases Curr Opin Pharmacol 10 308 315 20172761 10.1016/j.coph.2010.01.005 1:CAS:528:DC%2BC3cXptVWnu7k%3D
26. KA Appau VW Fazio B Shen, et al. 2008 Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients J Gastrointest Surg 12 1738 1744 18709420 10.1007/s11605-008- 0646-0
27. Z Yang Q Wu K Wu, et al. 2010 Meta-analysis: pre-operative infliximab treatment on short-term post-operative complications in patients with ulcerative colitis Aliment Pharmacol Ther 31 4 486 492 19925496 10.1111/j.1365-2036.2009. 04204.x 1:CAS:528:DC%2BC3cXitFKgsro%3D
28. Blonski W, Osterman MT, Lin MV, et al (2010) Risk of postoperative infections in IBD patients treated with perioperative anti-TNF therapy: a meta-analysis. Abstract DDW
29. AE Stuck CE Minder FJ Frey, et al. 1989 Risk of infectious complications in patients taking glucocorticosteroids Rev Infect Dis 11 954 963 2690289 10.1093/clinids/11.6.954 1:STN:280:DyaK3c7gtValug%3D%3D
30. R Reding LA Michel J Donckier, et al. 1990 Surgery in patients on long term steroid therapy: a tentative model for risks assessment Br J Surg 77 1175 1178 2224468 10.1002/bjs.1800771028 1:STN:280:DyaK3M%2FivVKmsw%3D%3D (Pubitemid 20340666)
31. S Post M Betzler B von Ditfurth G Schürmann, et al. 1991 Risks of intestinal anastomoses in Crohn's disease Ann Surg 213 1 37 42 1985536 10.1097/00000658-199101000-00007 1:STN:280:DyaK3M%2FptVCktw%3D%3D
32. T Yamamoto RN Allan MR Keighley, et al. 2000 Risk factors for intra-abdominal sepsis after surgery in Crohn's disease Dis Colon Rectum 43 1141 1145 10950014 10.1007/BF02236563 1:STN:280:DC%2BD3cvitVSnsA%3D%3D (Pubitemid 30626148)
33. A Alves Y Panis Y Bouhnik, et al. 2007 Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients Dis Colon Rectum 50 3 331 336 17252288 10.1007/s10350-006-0782-0 (Pubitemid 46393968)
34. G Heyvaert F Penninckx L Filez, et al. 1994 Restorative proctocolectomy in elective and emergency cases of ulcerative colitis Int J Colorectal Dis 9 2 73 76 8064193 10.1007/BF00699416 1:STN:280:DyaK2czkt1Oruw%3D%3D (Pubitemid 24157625)
35. JJ Tjandra VW Fazio JW Milsom, et al. 1993 Omission of temporary diversion in restorative proctocolectomy-is it safe? Dis Colon Rectum 36 11 1007 1014 8223051 10.1007/BF02047291 1:STN:280:DyaK2c%2FjvVChsA%3D%3D (Pubitemid 23335246)
36. JP Lake E Firoozmand JC Kang, et al. 2004 Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis J Gastrointest 8 5 547 551 10.1016/j.gassur.2004.01.002 (Pubitemid 38881409)
37. U Mahadevan EV Loftus Jr WJ Tremaine, et al. 2002 Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications Inflamm Bowel Dis 8 5 311 316 12479645 10.1097/00054725-200209000-00001
38. FN Aberra JD Lewis D Hass, et al. 2003 Corticosteroids and Immunomodulators: postoperative infectious complications risk in inflammatory bowel disease patients Gastroenterology 125 320 327 12891531 10.1016/S0016-5085(03)00883-7 1:CAS:528:DC%2BD3sXmvFygurc%3D (Pubitemid 36929411)
39. Y Ziv JM Church VW Fazio, et al. 1996 Effect of systemic steroids on ileal pouch-anal anastomosis in patients with ulcerative colitis Dis Colon Rectum 39 504 508 8620798 10.1007/BF02058701 1:STN:280:DyaK283gtlKktA%3D%3D
40. MJ Page LS Poritz SJ Kunselman, et al. 2002 Factors affecting surgical risk in elderly patients with inflammatory bowel disease J Gastrointest Surg 6 606 613 12127128 10.1016/S1091-255X(01)00060-9 (Pubitemid 40433515)
41. M Bruewer M Utech EJ Rijcjen, et al. 2003 Preoperative steroid administration: effect on morbidity among patients undergoing intestinal bowel resection for Crohn's disease World J Surg 27 1306 1310 14716499 10.1007/s00268-003-6639-y (Pubitemid 36961136)
42. V Subramanian S Saxena JY Kang, et al. 2008 Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery Am J Gastroenterol 103 2373 2381 18616660 10.1111/j.1572-0241.2008.01942.x